Market Overview

Actavis, Allergan Could Announce Merger Deal Monday

Related AGN
Teva Pharmaceuticals Has Had An Eventful 24 Hours
Key Exec Announcing His Retirement From Teva 'Creates More Uncertainties'
New Oral Psoriasis Drug Tops Cellceutix Catalysts (Seeking Alpha)

Actavis PLC (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) are close to a merger deal, according to The Wall Street Journal. The reported price for Allergan is $210 to $220, according to sources.

A deal between the two pharmaceutical companies would make it nearly impossible for Valeant Pharmaceuticals and investor Bill Ackman to takeover the combined company.

The announcement of a merger deal could come as early as Monday, reports persons familiar with the matter.

Actavis closed Friday at $243.77, a gain of $2.14 (0.89 percent), while Allergan shares gained $2.44 (1.24 percent) to close at $198.65.

Posted-In: News Wall Street Journal Rumors M&A Media


Related Articles (AGN + ACT)

View Comments and Join the Discussion!